Alamar Biosciences, Inc. (ALMR)
| Market Cap | 2.09B |
| Revenue (ttm) | 114.05M +353.6% |
| Net Income | -55.00M |
| EPS | -1.44 |
| Shares Out | 69.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,011 |
| Open | 31.94 |
| Previous Close | 31.76 |
| Day's Range | 30.10 - 31.94 |
| 52-Week Range | 18.85 - 39.61 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 37.00 (+22.92%) |
| Earnings Date | Nov 3, 2026 |
About ALMR
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnosti... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ALMR stock is "Buy." The 12-month stock price target is $37.0, which is an increase of 22.92% from the latest price.
News
Alamar Biosciences Transcript: UBS Global Healthcare Conference
Q3 revenue grew 68% YoY, with consumables up 79% and record gross margin of 61.5%. Large UK Biobank and GSK studies, new disease panels and planned end-2027 FDA submissions support the growth and diagnostics roadmap.
Alamar Biosciences to Participate in Upcoming Investor Conferences
Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced th...
Alamar Biosciences price target raised to $36 from $34 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Alamar Biosciences (ALMR) to $36 from $34 and keeps a Buy rating on the shares. The firm said they…
Alamar Biosciences reports Q3 EPS (19c), consensus (19c)
Reports Q3 revenue $33.55M, consensus $30.19M. Consumable revenue grew 79% to $17.8M, driven by strong demand for multiplex panels, while instrument revenue rose 50% to $8.5M on continued growth in…
Alamar Biosciences raises FY26 revenue view to $121M-$123M from $116M-$120M
Consensus for FY26 revenue is $118.58M. Alamar Biosciences (ALMR) now expects FY26 revenue of $121M-$123M, representing growth of 64% at the midpoint of the range vs. last year. “Our selection…
Alamar Biosciences partners with GSK on 60,000-sample proteomic study
Alamar Biosciences (ALMR) announced a strategic scientific collaboration with GSK (GSK) that will use Alamar’s NULISA platform in a large-scale study examining how circulating protein signatures relat...
Alamar Biosciences Earnings Call Transcript: Q3 2026
Q3 revenue rose 68% YoY, with consumables up 79% and gross margin reaching 61.5%. FY 2026 revenue guidance increased to $121M–$123M, alongside major UK Biobank and GSK study wins.
Alamar Biosciences Earnings release: Q3 2026
Alamar Biosciences released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Alamar Biosciences Slides: Q3 2026
Alamar Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Alamar Biosciences Quarterly report: Q3 2026
Alamar Biosciences has published its Q3 2026 quarterly earnings report on November 3, 2026.
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported fin...
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a ...
UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Supported The Michael J Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc, the study targets earlier detection, prevention and treatment of Parkinson's disease, Alzheimer's ...
Alamar Biosciences, Nightingale to lead U.K. Biobank neurodegenerative study
Alamar Biosciences (ALMR) and Nightingale Health announced the launch of the U.K. Biobank vanguard study to measure blood-based biomarkers that are of particular importance for neurodegenerative disea...
Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
FREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX: NHLTY, NGHLF) today announc...
Alamar Biosciences’ technology used in study detecting ALS with 98% accuracy
Alamar Biosciences (ALMR) announced researchers at Emory University have identified a 10-protein blood signature that distinguished patients with amyotrophic lateral sclerosis from healthy controls wi...
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations Pub...
Cathie Wood’s ARK Investment buys 101K shares of Alamar Biosciences today
21:10 EDT Cathie Wood’s ARK Investment buys 101K shares of Alamar Biosciences (ALMR) today
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it...
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership team with appointments of John Brottem as general cou...
Lancet study using Alamar’s technology reveals divergent responses to Alzheimers
The company states: “Alamar Biosciences (ALMR) announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients recei...
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from th...
Alamar Biosciences rises 15.1%
Alamar Biosciences (ALMR) is up 15.1%, or $4.82 to $36.83.
Alamar Biosciences rises 9.4%
Alamar Biosciences (ALMR) is up 9.4%, or $3.01 to $35.02.
Alamar Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The platform combines high sensitivity and multiplexing, targeting research growth and clinical diagnostics projected to reach $9B by 2035. 2026 priorities include 100 placements, higher utilization and assay expansion; FDA submission is targeted by end of 2027.